Tumour virus infections articles within Nature Reviews Clinical Oncology

Featured

  • Perspective |

    Patients with cancer have a high risk of morbidity and mortality from COVID-19. The rapid development of COVID-19 vaccines has provided new hope of mitigating the disease. Herein, the COVID19 and Cancer Clinical Trials Working Group calls for prioritization of patients with cancer, importantly including those participating in oncology clinical trials, for COVID-19 vaccination. The authors also provide operational COVID-19 vaccine guidance for patients participating in oncology clinical trials.

    • Aakash Desai
    • , Justin F. Gainor
    •  & Vivek Subbiah

  • Opinion |

    Human papillomavirus (HPV)-screening technologies and HPV vaccination are revolutionizing the management of cancers related to this virus, in particular, cervical neoplasms. At present, however, the effectiveness of these modalities is not optimal, owing to the limited scope of HPV-vaccination and cervical screening programmes. In this Perspectives, an international panel of experts describes for the first time a new campaign, termed 'HPV-FASTER', which aims to broaden the use of HPV vaccination coupled with HPV testing to women aged up to 30 years, and in some settings up to 50 years, with the aim of accelerating the reduction in the incidence of HPV infections and cervical cancer. The authors describe the evidence supporting this approach and details on how it might be implemented, discuss the opportunities—particularly in low-resource settings—and challenges associated with the strategy, and highlight key research gaps that need to be addressed in future studies.

    • F. Xavier Bosch
    • , Claudia Robles
    •  & Jack Cuzick

  • Review Article |

    Patients infected with HIV seem to develop certain types of cancer more frequently than uninfected people. Specifically, lymphomas represent the most frequent malignancy affecting patients with HIV. This Review focuses on the different type of lymphomas that generally occur in patients infected with HIV, as well as other cancers. The authors provide an update of epidemiological data and diagnostic issues, and discuss the most-appropriate strategies for the management of patients with both HIV and lymphomas.

    • Antonino Carbone
    • , Emanuela Vaccher
    •  & Silvia Franceschi

  • Review Article |

    Highly efficacious vaccines are available to protect against persistent human papillomavirus (HPV) infection and, therefore, the associated neoplasias (most notably cervical cancer). This Review article discusses the two approved vaccines in terms of their structure, mode of action, efficacy, cross-reactivity with non-vaccine HPV types, safety and use in vaccination programmes.

    • Matti Lehtinen
    •  & Joakim Dillner

Browse broader subjects

Browse Tumour virus infections across other nature.com journals